[Effectiveness of pefloxacin in brucellosis].
The clinical efficacy of pefloxacin in the treatment of 51 and 19 patients with acute and subacute brucellosis respectively was studied. It was shown that in a dose of 400 mg twice a day for 15 days pefloxacin provided a rapid regression of the brucellosis clinical signs. By the efficacy it was not inferior to the combination of doxycycline and rifampicin used in the routine doses. Pefloxacin had no toxic action on the function of the liver, kidneys and hematopoietic system. The side effects were minimal. Pefloxacin did not suppress the immunity. By decreasing the activity of the brucellosis process it promoted normalization of the immunological indices.
Kurmanova
K B
KB
Kkhamfyang
S
S
Iudin
S M
SM
D000208:Acute Disease; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002006:Brucellosis / Q000188:drug therapy* / Q000276:immunology; D004318:Doxycycline / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007109:Immunity / Q000187:drug effects; D008297:Male; D015366:Pefloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods; D012293:Rifampin / Q000627:therapeutic use; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D015366:Pefloxacin; D004318:Doxycycline; D012293:Rifampin
Effektivnost' pefloksatsina pri brutselleze.